Trial Profile

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Sponsors InnoCare Pharma

23 Aug 2022 Planned End Date changed from 1 Sep 2027 to 31 Dec 2027.
23 Aug 2022 Planned primary completion date changed from 1 Sep 2024 to 31 Dec 2024.
08 Dec 2021 Planned initiation date changed from 1 Sep 2021 to 30 Jan 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com